TrivarX Ltd. engages in clinical research, product development, and early-stage commercialization of mental health technology. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2001-01-29. Through the Company’s corporate health product, it offers mental well-being solutions for businesses and is also developing products to serve the healthcare provider market. The principal activity of the Company is development of artificial intelligence (AI)-driven, scientifically based devices for screening and diagnosis of behavioral health conditions. Its clinical research has enabled the development of proprietary algorithms for spectral analyses of sleep architecture and heart-rate variability. The Company’s lead product, MEB-001 analyses the data from a standard sleep study to identify depression at a sensitivity of over 85%. Its technology analyses the electrical signals from the brain and the heart to identify mental illness.
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for MDBIF. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: MDBIF is a Buy candidate.
MDBIF stock price ended at $0 on 星期二, after dropping 100.00%
On the latest trading day Jan 06, 2026, the stock price of MDBIF fell by 100.00%, dropping from $0.00 to $0.00. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $0.00 and a high of $0.00. On the latest trading day, the trading volume for MDBIF decreased by 11.6K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 337 shares were traded, with a market value of approximately --.